Gilead and Arcus Biosciences pulled back further on their TIGIT collaboration after STAR-121 failed in Phase 3 in metastatic NSCLC. In filings, Gilead cited futility and terminated the trial’s continuation pathway, prompting a broader rollback of programs tied to domvanalimab. The discontinued study tested domvanalimab in combination with a PD-1 blocker and chemotherapy against a control of Merck’s Keytruda plus chemotherapy. Arcus did not disclose additional results beyond the independent data panel’s futility determination, and the latest analysis reportedly did not include a safety assessment. Separately, the partners said the Phase 2 EDGE-Lung study of domvanalimab would also be ended, underscoring how quickly the TIGIT strategy is being trimmed after multiple prior setbacks in the class.